Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0.30%
- Poor long term growth as Net Sales has grown by an annual rate of -20.70% and Operating profit at 14.21% over the last 5 years
- The company is Net-Debt Free
- PRE-TAX PROFIT(Q) At CNY -10.26 MM has Fallen at -126.14%
- NET PROFIT(Q) At CNY -12 MM has Fallen at -133.15%
- NET SALES(Q) At CNY 86.34 MM has Fallen at -12.13%
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,709 Million (Large Cap)
35.00
NA
0.00%
6.58
601.76%
126.25
Revenue and Profits:
Net Sales:
108 Million
(Quarterly Results - Mar 2026)
Net Profit:
5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.25%
0%
5.25%
6 Months
-5.37%
0%
-5.37%
1 Year
43.54%
0%
43.54%
2 Years
329.76%
0%
329.76%
3 Years
151.57%
0%
151.57%
4 Years
121.47%
0%
121.47%
5 Years
17.21%
0%
17.21%
Hunan Jingfeng Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-20.70%
EBIT Growth (5y)
14.21%
EBIT to Interest (avg)
-1.61
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
5.50
Sales to Capital Employed (avg)
1.00
Tax Ratio
3.67%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.30%
ROE (avg)
44.62%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
105.21
EV to EBIT
-173.38
EV to EBITDA
-961.16
EV to Capital Employed
12.35
EV to Sales
14.46
PEG Ratio
0.22
Dividend Yield
NA
ROCE (Latest)
-7.12%
ROE (Latest)
303.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
107.50
106.30
1.13%
Operating Profit (PBDIT) excl Other Income
6.50
-45.50
114.29%
Interest
1.30
16.20
-91.98%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.70
-35.80
113.13%
Operating Profit Margin (Excl OI)
60.60%
-514.20%
57.48%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 1.13% vs 20.11% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 113.13% vs -222.52% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
375.10
412.40
-9.04%
Operating Profit (PBDIT) excl Other Income
-16.20
11.10
-245.95%
Interest
30.40
40.40
-24.75%
Exceptional Items
-30.20
238.80
-112.65%
Consolidate Net Profit
-79.00
159.40
-149.56%
Operating Profit Margin (Excl OI)
-127.10%
-43.80%
-8.33%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -9.04% vs -36.60% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -149.56% vs 170.07% in Dec 2024
About Hunan Jingfeng Pharmaceutical Co., Ltd. 
Hunan Jingfeng Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






